Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
6.10
-0.35 (-5.35%)
Aug 14, 2025, 11:26 AM - Market open
Dermata Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Dermata Therapeutics stock has a target of 30, which predicts a 391.80% increase from the current stock price of 6.1.
Price Target: $30 (+391.80%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 21, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Dermata Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $60 → $30 | Strong Buy | Maintains | $60 → $30 | +391.80% | May 21, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $100 → $60 | Strong Buy | Maintains | $100 → $60 | +883.61% | Aug 21, 2024 |
| Maxim Group | Maxim Group | Strong Buy Maintains $2,400 → $600 | Strong Buy | Maintains | $2,400 → $600 | +9,736.07% | Mar 23, 2023 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $33,600 | Strong Buy | Initiates | $33,600 | +550,719.67% | Sep 21, 2021 |
| Maxim Group | Maxim Group | Strong Buy Initiates $21,600 | Strong Buy | Initiates | $21,600 | +353,998.36% | Sep 14, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.40
from -80.32
EPS Next Year
-1.07
from -1.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | n/a | n/a |
| Avg | n/a | n/a |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -1.44 | -1.10 |
| Avg | -1.40 | -1.07 |
| Low | -1.34 | -1.03 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.